Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Core Insights - Metsera, Inc. has released positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog, showing significant weight loss and favorable tolerability [1][3] Group 1: Clinical Trial Results - MET-233i demonstrated a mean placebo-subtracted weight loss of up to 8.4% at Day 36, with individual responses reaching as high as 10.2% [1][5] - The drug exhibited a 19-day observed half-life, supporting the potential for once-monthly dosing [1][5] - Gastrointestinal adverse events were mild and primarily occurred in the first week of dosing, indicating rapid tolerance onset [5] Group 2: Dosing and Administration - The trial evaluated single doses from 0.15 mg to 2.4 mg and multiple doses from 0.15 mg to 1.2 mg given weekly over five weeks [2] - Anticipated starting doses of 0.15 mg and 0.3 mg showed tolerability results comparable to placebo [5] Group 3: Future Developments - Metsera plans to advance MET-233i as a monotherapy and in combination with MET-097i, with topline data from ongoing trials expected in late 2025 [3][5] - The company is also preparing to report topline clinical data from its ultra-long-acting GIP receptor agonist, MET-034i, in combination with MET-097i, anticipated in late 2025 [3][4] Group 4: Market Reaction - Following the announcement, Metsera's stock increased by 13.24%, reaching $31.13 [4]